Amino acid sequence(Pro20-Lys291, with C-terminal human IgG Fc)
PEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKAAAPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
80 kDa,150kDa(Reducing)
>95% by SDS-PAGE
PBS, pH7.4
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
CD19 is a type-I transmembrane glycoprotein of 95 kDa that belongs to the immunoglobulin superfamily and is widely expressed on B cells throughout most stages of B-cell differentiation, though its expression is down-regulated during their terminal differentiation to plasma cells. CD19 maps to chromosome 16p11.2, where it encodes a 540 amino acid protein with two extracellular C-type IgSF domains as well as a large, approximately 240 residue, cytoplasmic tail that exhibits extensive conservation between mice and humans. CD19 is a signal amplifying coreceptor whose expression is restricted to B cells and follicular dendritic cells. CD19 exists in a multimolecular complex with CD21 (complement receptor type 2, CR2), the tetraspanin CD81 and CD225 on the B cell surface. Via its interaction with CD21, CD19 serves as a signal transducing device for complement-conjugated antigen in B cells. Coligation of the BCR and the CD19/CD21 complex lowers the threshold for B cell activation by approximately two orders of magnitude. CD19 is a potential target for monoclonal antibody therapy, and preliminary data have demonstrated its effectiveness in B-cell depletion, making this an attractive therapy for autoimmune disorders and treatment of malignant B-cell lymphomas.CD19 serves as an attractive target for immunotherapy for many reasons: (1) It is expressed on most B-cell malignancies; (2) it is expressed in the B-cell lineage at an early stage, even before the expression of CD20; (3) it internalizes efficiently in lymphoma tumor models252; and (4) it is possibly involved in the development of B-cell cancers.
2e5 of transient transfected anti-CD19 ScFv CAR-293 cells were stained with 0.1ug FITC - CD19 Fc Chimera Protein, Human, (Cat. No. UA010211) and unlable respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). FITC signal was used to evaluate the binding activity.
2e5 of transient transfected anti- CD19 ScFv CAR-293 cells were stained with 0.01ug CD19 Fc Chimera Protein, Human (Cat. No. UA010042) (Fig. D). Alexa Fluor 647 signal was used to evaluate the binding activity.
2e5 of transient transfected anti- CD19 ScFv CAR-293 cells were stained with isotype and G4S Linker-Alexa Fluor® 488 (Fig. E and F). Alexa Fluor® 488 signal was used to evaluate the binding activity.